{
    "nct_id": "NCT06564623",
    "official_title": "A Pilot Study of Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers",
    "inclusion_criteria": "* Age ≥18 years\n* Must have a histologically- or cytologically, proven biliary tract cancer (BTC) previously treated with gemcitabine/cisplatin/anti-PD(L)1 therapy.\n* Must have evidence of radiological disease, must accept to have a tumor biopsy of an accessible lesion at baseline and on treatment.\n* Must have sufficient archival tumor tissue for next-generation sequencing (NGS) and immune-phenotyping.\n* Have a BTC containing at least one of the oncogenic mutation/alterations targeted by the vaccine.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Must have body weight of >30 kg.\n* Patients must have adequate organ and marrow function defined by study-specified laboratory tests.\n* Patients with chronic or acute hepatitis B virus (HBV) or hepatitis C virus (HCV) infection must have disease controlled prior to enrollment.\n* Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test.\n* For both Women and Men, must use acceptable form of birth control while on study.\n* Must have a life expectancy of at least 12 weeks.\n* Ability to understand and willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participation in another clinical study with an investigational product during the last 2 weeks.\n* Patient is expected to require any other form of systemic or localized antineoplastic therapy while on study.\n* Any of the following procedures or medications within 2 weeks prior to initiation of study treatment:\n\n  * Systemic or topical steroids at immunosuppressive doses (> 10 mg/day of prednisone or equivalent). The following are exceptions to this criterion:\n  * Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\n  * Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent\n  * Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n  * Palliative or adjuvant radiation or gamma knife radiosurgery.\n  * Chemotherapy or checkpoint inhibitor targeting anti-Pd1/PD-L1.\n* Within 4 weeks prior to initiation of study treatment:\n\n  * Any investigational cytotoxic drug.\n  * Any investigational device.\n  * Non-oncology vaccines containing live virus.\n  * Allergen hyposensitization therapy.\n  * Growth factors, e.g. granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), erythropoietin.\n  * Major surgery.\n* Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.\n* Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.\n* All AEs while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study.\n* Must not have experienced a ≥Grade 3 immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immunotherapy.\n* Patients with a history of prior treatment with anti-PD-1 and anti-PD-L1.\n* History of severe hypersensitivity reaction to any monoclonal antibodies or related compounds or to any of its components.\n* History of leptomeningeal carcinomatosis.\n* Patient has a known history or evidence of brain metastases.\n* Has an active known or suspected autoimmune disease or which has required systemic therapy in the last 5 years.\n* Known history of interstitial lung disease or of (non-infectious) pneumonitis that required steroids or current pneumonitis.\n* Has a pulse oximetry < 92% on room air.\n* Requires the use of home oxygen.\n* Has a known history of Human Immunodeficiency Virus (HIV)/AIDS\n* Has active co-infection with HBV (hepatitis B virus) and HCV (hepatitis C virus) or coinfected with HBV and hepatitis delta virus (HDV)\n* Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Patients who have been diagnosed with another cancer or myeloproliferative disorder in the past 5 years requiring systemic therapy or expected to require active therapy within the clinical study period.\n* Has a diagnosis of immunodeficiency.\n* Presence of any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft. Patients with a history of allogeneic hematopoietic stem cell transplant will be excluded.\n* Any other sound medical, psychiatric, and/or social reason as determined by the Investigator.\n* Patient is at the time of signing informed consent a regular user (including \"recreational use\") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).\n* Patient is unwilling or unable to follow the study schedule for any reason.\n* Pregnant or breastfeeding.\n* WOCBP and men with female partners (WOCBP) who are not willing to use contraception.\n* Evidence of clinical ascites requiring paracentesis in the last 4 weeks.\n* History of malignant bowel obstruction.",
    "miscellaneous_criteria": ""
}